Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| MRNA | Moderna, Inc. | -3.52% | 75.70 | 0.0% | $2400.05m | |
| NVAX | Novavax, Inc. | 10.33% | 173.41 | 99.2% | $1287.55m | |
| GILD | Gilead Sciences, Inc. | -2.31% | 69.24 | 1.0% | $527.60m | |
| AMGN | Amgen, Inc. | -1.10% | 240.91 | 1.3% | $509.95m | |
| REGN | Regeneron Pharmaceuticals, Inc. | -3.41% | 626.33 | 2.5% | $459.38m | |
| SRNE | Sorrento Therapeutics, Inc. | 6.91% | 13.73 | 1.8% | $446.16m | |
| BNTX | BioNTech SE | -2.48% | 81.11 | 0.0% | $402.65m | |
| VRTX | Vertex Pharmaceuticals, Inc. | -1.42% | 271.81 | 1.9% | $379.14m | |
| BIIB | Biogen, Inc. | -0.21% | 275.51 | 1.6% | $326.25m | |
| ILMN | Illumina, Inc. | 1.75% | 400.58 | 3.5% | $325.55m | |
| VXRT | Vaxart, Inc. | 8.60% | 9.66 | 0.0% | $325.14m | |
| IBIO | iBio, Inc. | -0.11% | 4.39 | 1.8% | $182.64m | |
| EBS | Emergent BioSolutions, Inc. | 9.56% | 134.35 | 6.4% | $177.28m | |
| SGEN | Seattle Genetics, Inc. | -1.71% | 162.24 | 6.1% | $172.11m | |
| ALXN | Alexion Pharmaceuticals, Inc. | -2.36% | 102.74 | 2.0% | $170.84m |
Company Profile
Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. Its pipeline includes CUDC-907, CA-4948, CA-170, and CA-327. The CUDC-907 pipeline is an orally available small molecule inhibitor of HDAC and PI3K enzymes. The CA-170 pipeline is an also an orally-available small molecule antagonist of PD-L1 and VISTA immune checkpoints. The company was founded on February 14, 2000 and is headquartered in Lexington, MA.